Singapore Class B Immediate Registration Route: Conditions and Fees

1. Key takeaways

Class B devices can take the Immediate route under two alternative conditions: first, holding one independent Reference Agency approval with at least 3 years of market history in that jurisdiction and no safety incidents, no deaths and no open FSCA; or second, holding two independent Reference Agency approvals. Both routes carry the same set of safety conditions: no safety issues, no death events, no open FSCA, and no record of prior rejection. The fee is SGD 1,000 plus the SGD 560 application fee, and registration is granted immediately upon submission.

• The Immediate route is the best value channel in the Singapore system, but its gate is measured in time rather than money: Condition A demands three years of market history, which cannot be bought, only waited out or bypassed through Condition B.
• Condition B is a trade of a second approval for three years of waiting, and whether that trade pays off must be calculated case by case.
• Standalone medical mobile applications of Class B or Class C enjoy the loosest threshold: a single independent Reference Agency approval is enough for immediate registration.
• The safety conditions operate as a veto: a product with an overseas recall that is still open cannot take the Immediate route even if it holds two approvals.
• The consequence of misjudging eligibility is not a fee top-up but the forfeiture of a registration that has already been granted, which is far more serious than a rejection.

2. Legal basis

The eligibility conditions for the Class B Immediate route are set out in GN-15 sections 4 to 6, with fees taken from the official HSA fees page. The table below consolidates the two alternative conditions, the shared safety conditions, the software exception and the consequence of non-compliance. For the software exception, the specific clause wording is subject to the official text.

3. Expert insights

Insight one: this is the highest-value channel in the Singapore system, but the threshold lies in time, not money.

The comparison is SGD 1,000 against SGD 3,900 for the Class B Full route, and registration is granted immediately upon submission, removing the 160-working-day evaluation entirely. For Chinese manufacturers with mature overseas products, this is the first choice. But Condition A requires three years of market history, and that threshold cannot be bought; it can only be waited for, or bypassed through Condition B.

Insight two: Condition B is a trade of a second approval for three years of time.

Many companies have never run this calculation: rather than waiting three years, or taking the Abridged route at SGD 2,010 over 100 working days, it may be better to invest in obtaining a second independent-agency approval. It should be noted that the cost and duration of the second approval vary by product, and whether it is worthwhile must be calculated case by case. We advise clients to place the cost of the second approval and the SGD 2,010 plus 100 working days on the same sheet and compare them directly.

Insight three: software enjoys the loosest threshold.

Under GN-15 (subject to the official text for the specific clause), standalone medical mobile applications, Class B or Class C, can take the Immediate route with just one independent Reference Agency approval, subject to the same safety and rejection conditions. For clients developing digital therapeutics and standalone diagnostic software, this is a channel worth evaluating first.

Insight four: the safety conditions are a one-vote veto.

Conditions A and B both carry the same set of safety requirements: no safety issues, no death events, no open FSCA, and no record of prior rejection. A product with an overseas recall that has not been closed cannot take the Immediate route even if it holds two approvals. This is also the logical extension of the requirement in GN-15 R14 Annex 4 to proactively disclose the AE/FSCA history, because HSA will cross-check it.

Insight five: the consequence of an eligibility error is forfeiture, not a fee top-up.

This must be made clear before submission: a misjudgement of route eligibility may lead to the forfeiture (forfeit) of a registration already granted. This is far more serious than a rejection, because it means the product has already reached the market and is then stripped of its authorisation.

4. Practical recommendations

• Run an Immediate-route eligibility checklist before submission: tick off item by item the number of independent approvals, the market history, the safety record and any rejection record.
• Obtain a written declaration of the manufacturer’s AE/FSCA history: this is a mandatory item of GN-15 Annex 4 Part 2 and also the basis for the eligibility judgement.
• Close any FSCA record before filing: an open FSCA is a hard gate for the Immediate route.
• Assess software product lines separately: standalone medical mobile applications need only one approval.
• Archive the eligibility justification: document the reasoning as the basis for later audits and change management.

5. Verification checklist

• □ The number of independent Reference Agency approvals has been counted (under the HSA counting rule)
• □ If Condition A is used, market history of at least 3 years has been confirmed with evidence
• □ It has been confirmed that the device has no safety issues and no death events
• □ It has been confirmed that there is no open FSCA
• □ It has been confirmed that there is no record of prior rejection by HSA or a Reference Agency
• □ Software products have been assessed for the standalone mobile application exception
• □ The eligibility justification has been documented and archived

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com